BDSX Q1 2026 Earnings Call Summary

Total Revenue: $25.6 million, a 42% year-over-year increase.
Diagnostic Testing Revenue: $22.3 million, up 37% year-over-year, driven by a 29% increase in test volumes (approximately 17.8 thousand tests).
Development Services Revenue: $3.3 million, nearly doubling year-over-year, attributed to contracted programs and new agreements.
Gross Margin: 84% (GAAP), 82% excluding one-time tax recovery, reflecting a 300 basis point improvement year-over-year.
Operating Expenses: $27.6 million, an 18% increase year-over-year, primarily due to sales and marketing expansion.
Net Loss: $7.8 million, a 30% improvement compared to the prior year.
Adjusted EBITDA: Loss of $4.1 million, a 35% improvement year-over-year.
Cash Position: $25.6 million in unrestricted cash, a 35% increase from the previous quarter.

Biodesix is focusing on three main objectives for 2026: driving top-line growth, improving operational efficiency, and advancing its pipeline.
The company continues to enhance its diagnostic testing business, particularly the Notify Lung test, which is gaining traction among pulmonologists and primary care providers.
A significant clinical validation study was published, reinforcing the effectiveness of the NotifyCDT test.
The company is expanding its sales force, adding approximately six representatives per quarter throughout 2026 to enhance market penetration.

Full-year 2026 revenue guidance has been raised to $108 million to $114 million, reflecting a 25% growth over 2025.
Continued progress towards adjusted EBITDA profitability is expected, driven by increasing sales productivity and expanded clinical evidence supporting the Notify Lung test.

While the company reported strong growth, there are ongoing challenges in educating primary care physicians (PCPs) about the use of Notify testing and interpreting results.
The overall lung cancer screening compliance remains low, with less than 20% of eligible patients participating, indicating a significant opportunity but also a challenge in driving adoption.
Weather-related disruptions in early 2026 impacted operations, particularly in late January and early February, which could have affected revenue generation.

The management highlighted the successful integration of learnings from the primary care channel, with a focus on building relationships with pulmonologists to facilitate patient referrals.
There is a strong emphasis on educating healthcare providers about the benefits of Notify testing, particularly for smaller nodules, which could lead to earlier diagnoses and better patient outcomes.
The company acknowledged the impact of weather on operations but expressed confidence in the team's ability to recover and maintain strong performance.
Questions from analysts indicated interest in understanding the balance between development services and diagnostic testing revenue, with management clarifying that growth expectations are primarily driven by diagnostic testing volumes.

BDSX — Biodesix, Inc.